Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OSIRIS THERAPEUTICS, INC.OSIR · Entity 158290 | President & CEO | July 10, 2017 | September 21, 2017 |
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Chief Operating Officer | February 28, 2019 | March 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OSIRIS THERAPEUTICS, INC.
Report date July 10, 2017 · Filed September 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.67 · Expires 2027-07-10 | Direct | 25,000 |
Reported balance
After 2017-07-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-10 · Grant · Acquired 25,000 · Balance 25,000 F1: 6,250 shares underlying this option shall vest on each of July 10, 2018, July 10, 2019, July 10, 2020, and July 10, 2021, subject to Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 6,250 shares underlying this option shall vest on each of July 10, 2018, July 10, 2019, July 10, 2020, and July 10, 2021, subject to Reporting Person's continued service through the applicable vesting date.
Verrica Pharmaceuticals Inc.
Report date February 28, 2019 · Filed March 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.32 · Expires 2029-02-27 | Direct | 68,260 |
Reported balance
After 2019-02-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-28 · Grant · Acquired 68,260 · Balance 68,260 F1: 25% of shares subject to the option shall vest on February 28, 2020 (the "Initial Vesting Date"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Initial Vesting Date, subject to the Reporting Person continuing to be a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of shares subject to the option shall vest on February 28, 2020 (the "Initial Vesting Date"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Initial Vesting Date, subject to the Reporting Person continuing to be a service provider through each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVADEL PHARMACEUTICALS PLC
Report date February 12, 2026 · Filed February 12, 2026
Section 16 reporting ended · disclosed 2026-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 1
1 source rowRow 1 · 2026-02-12 · Disposition to issuer · Disposed 78,905 · Balance 0 F1: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). F3: Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03 · Expires 2029-08-07 | IndirectBy Trust | 0 |
Reported balance
After 2026-02-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-12 · Disposition to issuer · Disposed 60,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5: The Options are held by a revocable trust of which the Reporting Person is trustee. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.48 · Expires 2030-08-07 | IndirectBy Trust | 0 |
Reported balance
After 2026-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-12 · Disposition to issuer · Disposed 42,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5: The Options are held by a revocable trust of which the Reporting Person is trustee. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.07 · Expires 2031-08-03 | IndirectBy Trust | 0 |
Reported balance
After 2026-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-12 · Disposition to issuer · Disposed 42,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5: The Options are held by a revocable trust of which the Reporting Person is trustee. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.79 · Expires 2032-08-03 | IndirectBy Trust | 0 |
Reported balance
After 2026-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-12 · Disposition to issuer · Disposed 42,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5: The Options are held by a revocable trust of which the Reporting Person is trustee. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.10 · Expires 2033-08-01 | IndirectBy Trust | 0 |
Reported balance
After 2026-02-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-12 · Disposition to issuer · Disposed 33,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5: The Options are held by a revocable trust of which the Reporting Person is trustee. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.32 · Expires 2034-07-30 | IndirectBy Trust | 0 |
Reported balance
After 2026-02-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-12 · Disposition to issuer · Disposed 11,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5: The Options are held by a revocable trust of which the Reporting Person is trustee. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.93 · Expires 2034-12-17 | IndirectBy Trust | 0 |
Reported balance
After 2026-02-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-12 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5: The Options are held by a revocable trust of which the Reporting Person is trustee. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.83 · Expires 2035-07-29 | IndirectBy Trust | 0 |
Reported balance
After 2026-02-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-12 · Disposition to issuer · Disposed 11,000 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5: The Options are held by a revocable trust of which the Reporting Person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer.
F2: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR").
F3: Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1.
F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).
F5: The Options are held by a revocable trust of which the Reporting Person is trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2026 Filed Feb 12, 2026 17:35 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,000 | Not disclosed Strike: $10.83 | Not disclosed |
DisclosureSEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 9 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Ordinary Shares · 11,000 shares Expires 2035-07-29 F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee. Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:35 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $10.93 | Not disclosed |
DisclosureSEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 8 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Ordinary Shares · 25,000 shares Expires 2034-12-17 F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee. Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:35 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,000 | Not disclosed Strike: $16.32 | Not disclosed |
DisclosureSEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 7 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Ordinary Shares · 11,000 shares Expires 2034-07-30 F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee. Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:35 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 33,000 | Not disclosed Strike: $14.10 | Not disclosed |
DisclosureSEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 6 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Ordinary Shares · 33,000 shares Expires 2033-08-01 F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee. Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:35 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 42,000 | Not disclosed Strike: $4.79 | Not disclosed |
DisclosureSEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 5 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Ordinary Shares · 42,000 shares Expires 2032-08-03 F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee. Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:35 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 42,000 | Not disclosed Strike: $8.07 | Not disclosed |
DisclosureSEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 4 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Ordinary Shares · 42,000 shares Expires 2031-08-03 F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee. Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:35 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 42,000 | Not disclosed Strike: $8.48 | Not disclosed |
DisclosureSEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 3 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Ordinary Shares · 42,000 shares Expires 2030-08-07 F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee. Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:35 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $2.03 | Not disclosed |
DisclosureSEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 2 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Ordinary Shares · 60,000 shares Expires 2029-08-07 F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee. Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:35 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerOrdinary Shares | 78,905 | $21.00 | $1,657,005.00 |
DisclosureSEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2 · kind: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). F3 · shares: Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1. F1 · price: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2 · price: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). Read SEC document |
| September 15, 2025 Filed Sep 15, 2025 19:54 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GiftStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $10.83 | $0.00 |
DisclosureSEC source: 0001104659-25-090116 · tm2526163-2_4seq1.xml · derivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,000 shares Expires 2035-07-29 F1 · derivative.exercise_date: The options shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 16:09 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $10.83 | $0.00 |
DisclosureSEC source: 0001104659-25-072692 · tm2522138-5_4seq1.xml · derivative · entry 2 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Ordinary Shares · 11,000 shares Expires 2035-07-29 F2 · derivative.exercise_date: The options shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 16:09 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantOrdinary Shares | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-072692 · tm2522138-5_4seq1.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,900 F1 · shares: Represents a restricted share award. The shares shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 16:22 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GiftStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $10.93 | $0.00 |
DisclosureSEC source: 0001104659-25-006709 · tm254584-1_4seq1.xml · derivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 25,000 shares Expires 2034-12-17 F1 · derivative.exercise_date: The options become exercisable in three equal annual installments on each of the first three anniversaries following the 12/17/2024 grant date, subject to the Reporting Person's continued service at each such vesting date. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 16:13 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseOrdinary Shares | 5,000 | $7.93 | $39,640.00 |
DisclosureSEC source: 0001104659-25-005248 · tm254051-1_4seq1.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,900 Read SEC document |
| December 24, 2024 Filed Dec 27, 2024 16:15 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GiftOrdinary Shares | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-132145 · tm2432060-1_4seq1.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,900 Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 16:20 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $10.93 | $0.00 |
DisclosureSEC source: 0001104659-24-130173 · tm2431478-1_4seq1.xml · derivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires 2034-12-17 F1 · derivative.exercise_date: The options become exercisable in three equal annual installments on each of the first three anniversaries following the 12/17/2024 grant date, subject to the Reporting Person's continued service at each such vesting date. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 07:00 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseOrdinary Shares | 3,000 | $10.19 | $30,567.60 |
DisclosureSEC source: 0001104659-24-126999 · tm2430449-1_4seq1.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,400 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.18 to $10.1899, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| September 15, 2024 Filed Sep 16, 2024 17:18 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GiftStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0001104659-24-100286 · tm2424180-1_4seq1.xml · derivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,000 shares Expires 2034-07-30 F1 · derivative.exercise_date: The options shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant (July 30, 2024), subject to the Reporting Person's continued service at such time. Read SEC document |
| July 30, 2024 Filed Aug 1, 2024 16:38 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0001104659-24-084944 · tm2420652-6_4seq1.xml · derivative · entry 2 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Ordinary Shares · 11,000 shares Expires 2034-07-30 F2 · derivative.exercise_date: The options shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time. Read SEC document |
| July 30, 2024 Filed Aug 1, 2024 16:38 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantOrdinary Shares | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-084944 · tm2420652-6_4seq1.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,400 F1 · shares: Represents restricted share units ("RSUs"). Each RSU represents the contingent right to receive one Ordinary Share upon vesting and settlement. The RSUs shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time. Read SEC document |
| September 01, 2023 Filed Sep 1, 2023 21:30 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GiftStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $14.10 | $0.00 |
DisclosureSEC source: 0001104659-23-097892 · tm2325379-2_4seq1.xml · derivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: ADSs · 33,000 shares Expires 2033-08-01 F1 · derivative.exercise_date: These options shall vest in full on the earlier to occur of (a) August 1, 2024 or (b) the date of the next annual general meeting of shareholders following the date of grant (August 1, 2023), subject to the Reporting Person's continued service on the Board of Directors at such time. F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:16 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $14.10 | $0.00 |
DisclosureSEC source: 0001104659-23-087286 · tm2322778-2_4seq1.xml · derivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: ADSs · 33,000 shares Expires 2033-08-01 F1 · derivative.exercise_date: Options shall vest in full on the earlier to occur of (a) August 1, 2024 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time. F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| May 09, 2023 Filed May 10, 2023 16:12 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseADSs | 2,500 | $14.76 | $36,900.00 |
DisclosureSEC source: 0001104659-23-058439 · tm2315307-1_4seq1.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,400 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 17:00 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GiftStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $4.79 | $0.00 |
DisclosureSEC source: 0001104659-23-006235 · tm234325-1_4seq1.xml · derivative · entry 7 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ADSs · 42,000 shares Expires 2032-08-03 F5 · derivative.exercise_date: These options shall vest in full on the earlier to occur of (a) August 3, 2023 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time. F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 17:00 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GiftStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $8.07 | $0.00 |
DisclosureSEC source: 0001104659-23-006235 · tm234325-1_4seq1.xml · derivative · entry 5 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ADSs · 42,000 shares Expires 2031-08-03 F1 · derivative.exercise_date: These options are fully vested and exercisable as of the date hereof. F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 17:00 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GiftStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $8.48 | $0.00 |
DisclosureSEC source: 0001104659-23-006235 · tm234325-1_4seq1.xml · derivative · entry 3 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ADSs · 42,000 shares Expires 2030-08-07 F4 · derivative.exercise_date: These options become exercisable as to 14,000 ADSs on each of the first three anniversaries after the 08/07/2020 grant date, subject to the Reporting Person's continued service at each such vesting date. F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 17:00 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GiftStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001104659-23-006235 · tm234325-1_4seq1.xml · derivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ADSs · 60,000 shares Expires 2029-08-07 F1 · derivative.exercise_date: These options are fully vested and exercisable as of the date hereof. F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 16:02 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseADSs | 2,000 | $7.20 | $14,405.00 |
DisclosureSEC source: 0001104659-22-130515 · tm2233557-1_4seq1.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,900 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 17:12 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $4.79 | $0.00 |
DisclosureSEC source: 0001104659-22-086771 · tm2222707-2_4seq1.xml · derivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: ADSs · 42,000 shares Expires 2032-08-03 F1 · derivative.exercise_date: Options shall vest in full on the earlier to occur of (a) August 3, 2023 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time. F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| May 27, 2022 Filed May 31, 2022 07:17 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseADSs | 10,000 | $1.60 | $16,000.00 |
DisclosureSEC source: 0001104659-22-066227 · tm2217241-4_4seq1.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,900 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 19:26 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $8.07 | $0.00 |
DisclosureSEC source: 0001179110-21-007964 · edgar.xml · derivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: ADSs · 42,000 shares Expires 2031-08-03 F1 · derivative.exercise_date: Options shall vest in full on the earlier to occur of (a) August 3, 2022 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time. F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| August 14, 2020 Filed Aug 17, 2020 18:58 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseADS | 2,500 | $7.94 | $19,849.75 |
DisclosureSEC source: 0001179110-20-009084 · edgar.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,900 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. F2 · balance_after: Includes 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 16:56 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $8.48 | $0.00 |
DisclosureSEC source: 0001179110-20-008889 · edgar.xml · derivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: ADSs · 42,000 shares Expires 2030-08-07 F1 · derivative.exercise_date: Options become exercisable as to 14,000 ADSs on each of the first three anniversaries after the 08/07/2020 grant date. F2 · derivative.underlying: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 16:29 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseADSs | 7,500 | $5.91 | $44,325.00 |
DisclosureSEC source: 0001104659-19-070213 · tm19244822_form4.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,400 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. F2 · balance_after: Includes 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 17:00 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001567619-19-016166 · doc1.xml · derivative · entry 2 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: ADSs · 60,000 shares Expires 2029-08-07 F3 · derivative.exercise_date: Options become exercisable as to 20,000 ADSs on each of the first three anniversaries after the 08/07/2019 grant date. F1 · derivative.underlying: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 17:31 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (Right to Buy) · Derivative | 68,260 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001209191-19-015814 · doc4.xml · derivative · entry 1 Palczuk Linda · CIK 0001717580 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,260 Underlying: Common Stock · 68,260 shares Expires 2029-02-27 F1 · derivative.exercise_date: 25% of shares subject to the option shall vest on February 28, 2020 (the "Initial Vesting Date"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Initial Vesting Date, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| January 16, 2019 Filed Jan 17, 2019 16:48 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 3,000 | $10.53 | $31,590.00 |
DisclosureSEC source: 0001209191-19-004240 · doc4.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $10.40 to $10.659, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: Consists of 3,000 shares of common stock held by Ms. Palczuk and 5,500 shares of common stock held by Ms. Palczuk jointly with her spouse. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 16:27 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 2,500 | $16.52 | $41,300.00 |
DisclosureSEC source: 0001209191-18-051471 · doc4.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 F1 · price: This transaction was executed in multiple trades at prices ranging from $16.52 to $16.55, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.direct: Consists of 3,000 shares of common stock held by Ms. Palczuk and 2,500 shares of common stock held by Ms. Palczuk jointly with her spouse. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 16:17 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantADSs | 27,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-035136 · doc1.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,900 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. F2 · shares: Represents 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date. Read SEC document |
| June 19, 2018 Filed Aug 15, 2018 16:48 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 3,000 | $15.00 | $45,000.00 |
DisclosureSEC source: 0001209191-18-046827 · doc4.xml · nonDerivative · entry 1 Palczuk Linda · CIK 0001717580 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| July 10, 2017 Filed Sep 21, 2017 15:54 UTC | OSIRIS THERAPEUTICS, INC. OSIR · Entity 158290 | GrantIncentive Stock Option (right to buy) · Derivative | 25,000 | $6.67 Strike: $6.67 | $166,750.00 |
DisclosureSEC source: 0001123292-17-001439 · edgar.xml · derivative · entry 1 Palczuk Linda · CIK 0001717580 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-07-10 F1 · derivative.exercise_date: 6,250 shares underlying this option shall vest on each of July 10, 2018, July 10, 2019, July 10, 2020, and July 10, 2021, subject to Reporting Person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.